The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. BridgeBio Pharma Inc shares valued at $11,512,443 were sold by HOMCY CHARLES J on Aug 08 ’25. At $46.05 per share, HOMCY CHARLES J sold 250,000 shares. The insider’s holdings dropped to 966,674 shares worth approximately $48.7 million following the completion of this transaction.
Also, HOMCY CHARLES J sold 50,000 shares, netting a total of over 2,400,000 in proceeds. Following the sale of shares at $48.00 each, the insider now holds 916,674 shares.
Before that, Apuli Maricel had sold 1,000 shares from its account. In a trade valued at $45,440, the Chief Accounting Officer traded BridgeBio Pharma Inc shares for $45.44 each. Upon closing the transaction, the insider’s holdings decreased to 1,000 shares, worth approximately $7.15 million.
Analysts at Truist started covering the stock with ‘”a Buy”‘ outlook in a report released in late July. As of July 14, 2025, Jefferies has initiated its “Buy” rating for BBIO. Earlier on July 09, 2025, Oppenheimer upgraded its rating. Their new recommendation was “an Outperform” for BBIO stock which previously was a “a Perform”.
Analyzing BBIO Stock Performance
On last trading session, BridgeBio Pharma Inc [NASDAQ: BBIO] rose 2.63% to $50.38. The stock’s lowest price that day was $49.125, but it reached a high of $50.51 in the same session. During the last five days, there has been a surge of approximately 12.43%. Over the course of the year, BridgeBio Pharma Inc shares have jumped approximately 106.22%. Shares of the company reached a 52-week high of $50.51 on 08/13/25 and a 52-week low of $27.53 on 01/02/25.
Support And Resistance Levels for BridgeBio Pharma Inc (BBIO)
According to the 24-hour chart, there is a support level at 49.49, which, if violated, would cause prices to drop to 48.59. In the upper region, resistance lies at 50.89. The next price resistance is at 51.40. RSI (Relative Strength Index) is 65.97 on the 14-day chart, showing neutral technical sentiment.
Is BridgeBio Pharma Inc subject to short interest?
Stocks of BridgeBio Pharma Inc saw a sharp steep in short interest on 2025-07-31 dropping by -3.32 million shares to 18.52 million. Data from Yahoo Finance shows that the short interest on 2025-06-30 was 21.83 million shares. A decline of -17.9% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 7.46 of the overall float, the days-to-cover ratio (short ratio) decline to 7.46.
Which companies own the most shares of BridgeBio Pharma Inc (BBIO)?
In terms of BridgeBio Pharma Inc share price expectations, FactSet research, analysts set an average price target of 72 in the next 12 months, up nearly 46.67% from the previous closing price of $49.09. Analysts anticipate BridgeBio Pharma Inc stock to reach 72 by 2025, with the lowest price target being 72. In spite of this, 9 analysts ranked BridgeBio Pharma Inc stock as Buy at the end of 2025. On June 17, 2025, Wolfe Research assigned a price target of “an Outperform” to the stock and initiated coverage with a $49.
